Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the list of selected units for the second batch of the innovative task for biomedical materials, highlighting Jiangsu's leading position in this field with 20 projects selected, the highest in the country [1] Group 1: Project Overview - The biomedical materials innovation task aims to address critical technological challenges in the field and select the most capable innovators for focused breakthroughs in high-end medical materials [1] - Jiangsu's selected projects cover 14 categories of biomedical materials across three directions: inorganic non-metallic materials, polymer materials, and metal materials [1] Group 2: Application and Market Potential - These biomedical materials are widely used in high-value medical devices such as artificial joints, vascular stents, artificial bone repair, oral repair, and wound repair, indicating significant clinical application value and market promotion potential [1] - The increase in the number of applications and selections from Jiangsu compared to the previous round demonstrates substantial growth and potential for new growth points in the integration of new material clusters and biomedicine clusters [1] Group 3: Support and Development - Selected enterprises will receive policy support in financing, review, and registration after completing their tasks, which will accelerate the market launch process of biomedical materials and medical device products in Jiangsu [1]

Core Insights - Jiangsu province has demonstrated a leading advantage and innovative strength in the field of biomedical materials, with 20 projects successfully selected from 86 total projects in the second batch of the national "Innovation Task" initiative [1] Group 1: Project Overview - The "Innovation Task" project is a major national innovation initiative aimed at addressing critical technological challenges in the biomedical materials sector [1] - The selected projects from Jiangsu cover 14 categories of biomedical materials, including inorganic non-metallic materials, polymer materials, and metal materials [1] Group 2: Applications and Market Potential - The biomedical materials have significant clinical application value and market promotion potential, being widely used in high-value medical devices such as artificial joints, vascular stents, artificial bone repair, oral repair, and wound repair [1] - The increase in the number of applications and selections from Jiangsu indicates a substantial improvement compared to previous submissions, highlighting the province's growing capabilities in this sector [1] Group 3: Support and Development - Selected companies will receive policy support in financing, evaluation, and registration after completing their innovation tasks, which will accelerate the market launch of biomedical materials and medical device products in Jiangsu [1]

扬子晚报网 9 月 10 日讯（记者 徐兢）9 月 10 日，记者从江苏省工信厅获悉，近日，工业和信息化部、国家药品监督管理局公示了生物医用材料创新任务 揭榜挂帅（第二批）入围单位名单，江苏省20个项目成功入选，数量居全国第一，占全国总数的近1/4（全国共86项），充分彰显了江苏在生物医用材料 领域的领先优势和创新实力。 为加快我国生物医用材料研制生产及应用进程，推进生物医用材料上下游协同创新攻关，工信部、国家药监局今年联合开展了生物医用材料创新任务揭榜 挂帅（第二批）工作。江苏省工信厅会同省药监局广泛动员、精心摸排、跟进服务，申报数与入选数均较上次有大幅提升。申报企业入围揭榜单位并完成 攻关任务后，这批揭榜优胜单位后续将得到融资、审评、注册等相应政策支持，加速江苏省生物医用材料及医疗器械产品的上市进程。 三、无机非金属材料方向 校对 石伟 | 纳米羟基磷灰石 | 苏州鼎安科技有限公司 | | --- | --- | | | 常州集硕医疗器械有限公司 | | 无机非金属涂层材料 | 苏州奥芮济医疗科技有限公司 | | | 苏州英诺科医疗科技有限公司 | 江苏20个项目入选国家生物医用材料创新任务"揭榜挂帅" ...

Core Viewpoint - The article discusses the current state and future trends of the biomedical materials industry in China, highlighting the competitive landscape and the significance of various material types in the market [1][3]. Group 1: Industry Overview - The biomedical materials industry is categorized into five main types: metal materials, polymer materials, medical ceramics, composite materials, and medical-derived materials [1]. - In 2022, metal and polymer materials held a significant share in the biomedical materials market, while composite and bio-derived materials are expected to gain market share due to technological advancements and increased demand in the medical aesthetics sector [3]. Group 2: Innovation and Competitiveness - The Ministry of Industry and Information Technology and the National Medical Products Administration have initiated a collaborative innovation task for biomedical materials, with a notable number of polymer material companies leading in the selection of innovation tasks [6]. - Companies from Beijing and Shandong provinces have shown strong competitiveness, as they have the highest number of selected units in the first batch of innovation tasks [7]. Group 3: Market Development Trends - The development trends for various types of biomedical materials in China are as follows: - Metal materials are focusing on high-strength, low-modulus, bioactive modifications, and biodegradable alloys to enhance long-term compatibility of implants and reduce the need for secondary surgeries [13]. - Polymer materials are evolving towards high functionality, smart responsive designs, and biodegradable controls to meet the precise needs of medical applications [13]. - Medical ceramics are enhancing bioactivity, nanoscale modifications, and optimizing porous structures for complex tissue engineering applications [13]. - Composite materials are centered on low-cost mass production and high-performance multifunctional integration for advanced medical devices [13]. - Medical-derived materials are transitioning from passive repair to active induction through intelligent regeneration systems, integrating personalized medicine and tissue regeneration technologies [13].

Core Insights - The Ministry of Industry and Information Technology and the National Medical Products Administration announced the second batch of selected units for the innovative task of biomedical materials, with Suzhou securing 15 positions, representing 17.4% of the national total and 75% of Jiangsu Province's entries, highlighting Suzhou's strong innovation capabilities in the biomedical materials sector [1][2]. Group 1: Innovations in Biomedical Materials - Peijia Medical's micro-nano fiber composite material was selected, showcasing its uniqueness in the valve industry and addressing critical clinical challenges in heart valve applications [1][2]. - Peijia Medical's new polymer valve technology, which uses non-biological, inorganic materials, significantly reduces production costs and is expected to have a longer lifespan than current biological valves, potentially decreasing the need for repeat surgeries [2]. - Haiwang Medical's newly developed block polyether amide resin aims to break the reliance on imported medical polymer materials, targeting a market previously dominated by French companies, with a market size exceeding 10 billion [2]. Group 2: Support for New Material Development - Suzhou has implemented the "Guidance Directory for the First Batch of Key New Material Application Demonstration," providing recognition support and financial incentives to stimulate enterprise investment in key material research [3]. - The new materials industry has emerged as Suzhou's third trillion-level industrial cluster, following electronic information and equipment manufacturing [3].

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 名额有限 三、团队科研成果的转化案例分享 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 2025年3月19日，思宇MedTech和Medtec China联合主办的 2025医疗器械研发论坛 上， 北京航空航天大学生物与医学工程学院教授、博士生导师牛旭锋 ，分享了题为 《生物医用材料创新如何推动植入介入器械的发展》 的精彩内容。 思宇MedTech提炼分享要点回顾如下，希望对医疗器械行业读者有所启发。 一、医疗器械与生物医用材料的现状分析 牛教授首先介绍了医疗器械行业的发展背景，强调医学与工程技术深度融合的重要性。 二、生物医用材料的应用方向和市场需求 牛教授重点介绍了团队的三个具体转化案例： 1、药物载体的设计与应用： 2、诊疗一体化柔性电极： 分析指出中国医疗器械产业规模与国际对比仍有差距，特别是国内医疗器械的药械比明 显低于发达国家，说明高端医疗器械国产替代空间巨大。 生物医用材料是医疗器械领域的关键组成部分，主要包括四类材料：医用金属材料、无 机非金属材料、高分子材料及复合材料。 牛教授指出，目前国内 ...